• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Jenusaitis Matthew bought $10,010 worth of Common Stock (1,300 units at $7.70), increasing direct ownership by 37% to 4,842 units

    8/27/21 3:19:33 PM ET
    $HJLI
    Medical/Dental Instruments
    Health Care
    Get the next $HJLI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Jenusaitis Matthew

    (Last) (First) (Middle)
    C/O JAFFE LABORATORIES,
    70 DOPPLER

    (Street)
    IRVINE CA 92618

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Hancock Jaffe Laboratories, Inc. [ HJLI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/25/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $$0.00001 par value 08/25/2021 P 1,300(1) A $7.7 4,842 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On August 25, 2021, the reporting person purchased 1,300 shares of common stock in the public market at $7.70 per share.
    /s/ Matthew Jenusaitis 08/27/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HJLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HJLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HJLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enVVeno Medical Corporation Successfully Completes Rebranding

      Company Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe Laboratories, Inc.For shareholders of the Company holding shares in electronic form, the name change will require no action. Shareholders with physical stock certificates should contact the Company's transfer agent to obtain new certificates.For more i

      10/1/21 7:02:00 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

      Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann on Monday, September 27, 2021 at 1:00 PM ET.The webinar will be moderated by Jeffrey S. Cohen, Managing Director of Ladenburg Thalmann. Following the discussion, there will be a question and answer se

      9/24/21 9:00:00 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

      - Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which

      9/21/21 4:00:00 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gray Robert converted options into 1,042 units of Common Stock, increasing direct ownership by 19% to 6,614 units

      4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)

      9/15/21 9:50:12 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Jenusaitis Matthew converted options into 1,042 units of Common Stock, increasing direct ownership by 22% to 5,884 units

      4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)

      9/15/21 9:50:17 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Jenusaitis Matthew bought $10,010 worth of Common Stock (1,300 units at $7.70), increasing direct ownership by 37% to 4,842 units

      4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)

      8/27/21 3:19:33 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    SEC Filings

    See more
    • Hancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      10/1/21 5:29:00 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)

      9/22/21 8:15:22 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Hancock Jaffe Laboratories, Inc.

      8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)

      9/8/21 4:49:36 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    Financials

    Live finance-specific insights

    See more
    • Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

      - Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which

      9/21/21 4:00:00 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

      Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m. ET.As part of the call, management will discuss VenoValve's continued development and other ongoing corporate initiatives. The call will be led by Robert Berman, Chief Executive Officer of Hancock Jaffe, who will be joined by Dr. Marc Glickman

      9/15/21 8:05:00 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care

    $HJLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hancock Jaffe Laboratories, Inc.

      SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)

      9/17/21 5:08:01 PM ET
      $HJLI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)

      2/19/21 11:44:25 AM ET
      $HJLI
      Medical/Dental Instruments
      Health Care